Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors.

ABSTRACT: Antiangiogenic therapies have failed to confer survival benefits in patients with metastatic breast cancer (mBC). However, to date, there has not been an inquiry into the roles for acquired versus innate drug resistance in this setting. In this study, we report roles for these distinct phenotypes in determining therapeutic response in a murine model of mBC resistance to the antiangiogenic tyrosine kinase inhibitor sunitinib. Using tumor measurement and vascular patterning approaches, we differentiated tumors displaying innate versus acquired resistance. Bioluminescent imaging of tumor metastases to the liver, lungs, and spleen revealed that sunitinib administration enhances metastasis, but only in tumors displaying innate resistance to therapy. Transcriptomic analysis of tumors displaying

SUBMITTER: Wragg JW 

PROVIDER: S-EPMC5321582 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature